Cingulate price target lowered to $10 from $11 at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Cingulate (CING) to $10 from $11 but keeps a Buy rating on the shares. The firm’s post-Q2 call with the company’s management has further strengthened its conviction for CTx-1301 regulatory acceptance in October and potential approval by mid-2026, the analyst tells investors in a research note. Assuming the NDA receives acceptance with an assigned PDUFA date, Roth expects a slew of launch preparation activities focused on disseminating CTx-1301’s value in the crowded ADHD market, the firm added.